[
    [
        {
            "time": "",
            "original_text": "主营业务拉升 健帆生物上半年净利增逾四成",
            "features": {
                "keywords": [
                    "主营业务",
                    "健帆生物",
                    "净利",
                    "增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "主营业务拉升 健帆生物上半年净利增逾四成",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物：肝病、危重症、海外市场增长提速",
            "features": {
                "keywords": [
                    "健帆生物",
                    "肝病",
                    "危重症",
                    "海外市场",
                    "增长提速"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：肝病、危重症、海外市场增长提速",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "西南证券维持健帆生物买入评级，近期获5份券商研报关注，目标均价涨幅23.56%",
            "features": {
                "keywords": [
                    "西南证券",
                    "健帆生物",
                    "买入评级",
                    "券商研报",
                    "目标均价涨幅"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券维持健帆生物买入评级，近期获5份券商研报关注，目标均价涨幅23.56%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "健帆生物：业绩符合预期 肝病业务拓展顺利",
            "features": {
                "keywords": [
                    "健帆生物",
                    "业绩",
                    "肝病",
                    "业务拓展"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：业绩符合预期 肝病业务拓展顺利",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物：单一产品贡献9成收入和毛利，集采危机两个万股价下跌超40% 经营问题",
            "features": {
                "keywords": [
                    "健帆生物",
                    "单一产品",
                    "收入",
                    "毛利",
                    "集采危机",
                    "股价下跌"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "单一产品贡献9成收入和毛利，集采危机两个万股价下跌超40% 经营问题",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "高瓴大手笔减持，刘格菘坚守！独霸市场械细分龙头，逻辑坏了？ 减持股份",
            "features": {
                "keywords": [
                    "高瓴",
                    "减持",
                    "刘格菘",
                    "医疗器械",
                    "细分龙头",
                    "逻辑坏了"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "高瓴大手笔减持，刘格菘坚守！独霸市场械细分龙头，逻辑坏了？ 减持股份",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "禁买线预警，看“聪明钱”如何爆买A股？",
            "features": {
                "keywords": [
                    "禁买线",
                    "聪明钱",
                    "A股"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "股票市场"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "禁买线预警，看“聪明钱”如何爆买A股？",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "健帆生物狂泻40%，遭高瓴连续减持，5倍牛股为何不受待见了？ 连续下跌",
            "features": {
                "keywords": [
                    "健帆生物",
                    "高瓴",
                    "减持",
                    "牛股",
                    "连续下跌"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "健帆生物狂泻40%，遭高瓴连续减持，5倍牛股为何不受待见了？ 连续下跌",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "中泰证券维持健帆生物买入评级：肾病肝病灌流持续高增长，脓毒症产品或成长期驱动力",
            "features": {
                "keywords": [
                    "中泰证券",
                    "健帆生物",
                    "买入评级",
                    "肾病",
                    "肝病",
                    "灌流",
                    "脓毒症",
                    "长期驱动力"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券维持健帆生物买入评级：肾病肝病灌流持续高增长，脓毒症产品或成长期驱动力",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物2021半年报点评：血液灌流器业务稳定增长 净利率持续提升",
            "features": {
                "keywords": [
                    "健帆生物",
                    "半年报",
                    "血液灌流器",
                    "业务稳定增长",
                    "净利率提升"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物2021半年报点评：血液灌流器业务稳定增长 净利率持续提升",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[健帆生物]中报利润端基本符合预期，肾病实现稳定增长 [安信医药马帅团队]",
            "features": {
                "keywords": [
                    "健帆生物",
                    "中报",
                    "利润",
                    "肾病",
                    "稳定增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[健帆生物]中报利润端基本符合预期，肾病实现稳定增长 [安信医药马帅团队]",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "高瓴连续4个季度减持 股价阴跌不止 健帆生物为何遭抛弃？ 减持股份",
            "features": {
                "keywords": [
                    "高瓴",
                    "减持",
                    "股价",
                    "阴跌",
                    "健帆生物"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "高瓴连续4个季度减持 股价阴跌不止 健帆生物为何遭抛弃？ 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "健帆生物盘中快速下跌",
            "features": {
                "keywords": [
                    "健帆生物",
                    "盘中",
                    "快速下跌"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "健帆生物盘中快速下跌",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "[国金晨讯]分化与融合并进下的通信行业投资机遇；上调信义光能盈利预测",
            "features": {
                "keywords": [
                    "国金晨讯",
                    "通信行业",
                    "投资机遇",
                    "信义光能",
                    "盈利预测"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "通信",
                    "能源"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[国金晨讯]分化与融合并进下的通信行业投资机遇；上调信义光能盈利预测",
                "Correlation": 1,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 2,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]